Resources

A multiple myeloma candidate with a new mode of action is now in Phase 2 patient trials following positive Phase 1 results showing it kills cancer cells without toxicity to patients.

The Cell and Gene Therapy Catapult is launching a Technology Advisory Board to accelerate the UK’s leadership in advanced therapies.

BioLife Solutions has entered into a multi-year supply agreement with Qkine Limited.

Harness Therapeutics nominates HRN001 as its lead drug candidate for Huntington's disease and the formation of a clinical advisory board to support advancement towards clinical evaluation.

ARC has launched Motherlabs Oxford, a new purpose-built life sciences accelerator space at its ARC Oxford campus, expanding its early-stage laboratory offering in response to sustained demand across the sector.

In this blog, Emily Klein, Senior Policy and Public Affairs Executive at BIA, explores the hidden, wide-ranging impacts and costs of rare diseases to society and the wider economy in the UK.

Complement Therapeutics GmbH (CTx) has received Clinical Trial Authorisation (CTA) approval in the United Kingdom for CTx001.

Collaboration to Deliver High-Quality Cytokines and Growth Factors to Enable the Advancement of Stem Cell-Based Therapeutics

Poolbeg Pharma (AIM: POLB), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the publication of a peer-reviewed paper from the POLB 001 LPS human challenge trial in Frontiers in Immunology.

The Cell and Gene Therapy Catapult (CGT Catapult) has published new insights into the UK’s CGT clinical trials in its 2025 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database.

ELRIG announced the keynote speakers for Cell and Gene Therapy 2026 - Drs Stephen Ward (Cell and Gene Therapy Catapult) and Annarita Miccio (Imagine Institute).

AAVantgarde Bio, a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs), has announced the completion of enrollment in LUCE-1.

Complement Therapeutics is one of the leading new gene therapy companies entering into clinical trials. Based on research from the University of Manchester, the company's lead candidate CTx001 is a novel adeno-associated virus (AAV)-based gene therapy targeting an advanced form of dry AMD that leads to irreversible vision loss, with limited therapeutic options. With strong funding and an experienced management team, Complement has made rapid progress and this Fast Track designation comes after IND clearance in December.

Ikarovec Ltd and VectorBuilder entered into an exclusive worldwide option agreement for VectorBuilder’s novel AAV capsid technology to be used with Ikarovec’s gene therapy candidate IKAR-003.

eXmoor Pharma and UCL have launched a new partnership to strengthen the pathway from academic research to GMP delivery, giving UCL innovators earlier access to CMC expertise, development capabilities and clinical manufacturing support to accelerate the translation of cell and gene therapies.

Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, has established a consortium to demonstrate how safety tests that detect potentially dangerous undifferentiated residual cells, which can affect product purity, could be applied to a range of a cell therapies.

Cellular Origins, a TTP company that enables the manufacturing of cell therapies at scale, has completed a $40 million (EUR 34.3 million) over-subscribed Series A round.

Poolbeg Pharma will act as the lead business partner, alongside Johnson & Johnson and other partners, on The University of Manchester and The Christie NHS Foundation Trust research programme which will facilitate wider research into cancer immunotherapy-induced CRS and the safer delivery of these treatments.

BIA thought leadership takes centre stage with two key reports published: last week saw the release of 'From innovation to impact: unlocking patient access to innovative rare disease medicines', and today 'UK cell and gene therapy: driving efficiencies and innovation' celebrates real-world UK success.

Our latest report demonstrates the real-world success and scalable manufacturing available in the UK’s globally competitive ecosystem.